Entries by Sara Hathaway, PharmD
NCPDP Updates DAW Code Definitions to Encompass Interchangeable Biosimilars
While this chart is useful, you may be asking yourself – What does this all mean?! Let us go through several examples.
Be Prepared for Audits on Pharmacist-Prescribed Paxlovid
As pharmacies across the country are gaining access to this anti-viral COVID-19 therapeutic agent, it is important to understand the specifications of the EUA…
DMEPOS Targeted Probe and Educate Program – Process Improvement Plan
There has been a sharp increase in the number of Targeted Probe and Educate Program audits on diabetic testing supplies.
New Tools Available! Biologic and Non-Biologic Injectable Medication Reference Charts
Ever wonder if you were billing the correct NDC for a Humira® prescription and had to spend precious time investigating? Or how about questioning if you were billing the correct package size for Gvoke® and had to consult multiple references just to try and figure out the answer?
Beyond-Use Date vs. Nursing Home Storage Policy – Avoid this Recoupment Trap!
Manufacturers go through rigorous testing to bring their products to market and part of the tedious approval process includes stability, sterility, and beyond-use date (BUD) testing.
Best Practice for Entering Transfers with Partial Refills Remaining
Transfer prescriptions carry a high audit risk due to the additional documentation required based on state regulations.
Updated COVID-19 Vaccine Attestations Plus Resource and Billing Chart on PAAS Member Portal
On March 29, 2022, the CDC and FDA issued press releases to provide updated COVID-19 vaccine recommendations.
Hackers Don’t Sleep, Your PHI is At Risk! What Are Your Safeguards?
Pharmacies, big and small, may find themselves on the probing end of a hacker’s criminal scheme designed to access and steal protected health information (PHI).
Options for DMEPOS Orders with Quantities Above Policy Limits
Medicare has strict coverage qualifications and limitations for items covered by Part B.
